Clinical trial · Interventional
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
NCT02638428CI-TRIAL-00044141unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Refractory Pediatric AML | Childhood Acute Myeloid Leukemia | CURATED_BROADER | 0.78 |
| Refractory Pediatric Solid Tumor | Childhood Solid Neoplasm | CURATED_BROADER | 0.80 |
| Relapsed Pediatric AML | Childhood Acute Myeloid Leukemia | CURATED_BROADER | 0.78 |
| Relapsed Pediatric Solid Tumor | Childhood Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (18)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Axitinib | Drug | Axitinib | ALIAS |
| CancerSCAN™ | Procedure | — | UNRESOLVED |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Crizotinib | Drug | Crizotinib | ALIAS |
| Cytarabine | Drug | Cytarabine | ALIAS |
| Dasatinib | Drug | Dasatinib | ALIAS |
| Erlotinib | Drug | Erlotinib | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Everolimus | Drug |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Refractory/relapsed solid tumor or AML
- description
- Conventional chemotherapy (Ifosfamide carboplatin etoposide for solid tumor and fludarabine cytarabine for AML) with matched single-targeted agent (axitinib, crizotinib, dasatinib, erlotinib, everolimus, imatinib, pazopanib, ruxolitinib, sorafenib, vandetanib, vemurafenib, or trastuzumab) or multi-targeted receptor tyrosine kinase inhibitor (pazopanib or sorafenib) according to the result of CancerSCAN™
- interventionNames
- Procedure: CancerSCAN™
- Drug: Ifosfamide
- Drug: Carboplatin
- Drug: Etoposide
- Drug: Fludarabine
- Drug: Cytarabine
- Drug: Pazopanib
- Drug: Sorafenib
- Drug: Axitinib
- Drug: Crizotinib
- Drug: Dasatinib
- Drug: Erlotinib
- Drug: Everolimus
- Drug: Imatinib
- Drug: Ruxolitinib
- Drug: Vandetanib
- Drug: Vemurafenib
- Drug: Trastuzumab
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Under 18 years of age at initial diagnosis * Patients with refractory/relapsed solid tumor or AML (Solid tumor: Stable or progressive disease after 1st-line treatment or relapse; AML: Persistence after 2 cycles of induction chemotherapy or relapse) * Patient with tumor sample which is adequate for targeted deep sequencing Exclusion Criteria: * Patients who had salvage chemotherapy previously * Patients with organ dysfunction as follows (creatinine elevation ≥ 3 x upper limit of normal (ULN), ejection fraction \<40%, significant arrhythmia or conduction disturbance) * Patients who are not eligible to have scheduled treatment due to the other significant impaired organ function * Patients whose tumor samples are not sufficient for targeted deep sequencing * Pregnant or nursing women
References
Publications (0)
Data not yet available
No reference posted for this study.